ISTH 2025 Supported Symposia & Presentation Theaters
​

The following companies will organize supported symposia and/or presentation theater sessions at the ISTH 2025 Congress in Washington, D.C., showcasing the latest scientific, diagnostic and therapeutic advances in thrombosis and hemostasis. 

​

See below for session titles, dates and times.

 

Sunday, June 22, 7:00 – 7:45  |  Supported Symposia​

• From Breakthroughs to Resolution of Bleeds: Hemophilia Inhibitor Patients in the Age of Non-Factor Prophylaxis (Hema Biologics) 
  Room 203 A & B

​

Sunday, June 22, 12:15 – 13:30  |  Supported Symposia

• Evolving the Standard of Care in the Age of Non-Factor Therapies (Novo Nordisk)
  Room 201

• ☆ A New Dawn in Hemophilia Care: Exploring the Impact of Antithrombin Lowering  (Sanofi)
  Room 202 A & B

• Developing a Novel Ultra-Long Half-Life rFVIII for Hemophilia A (Octapharma)
  Room 204 A, B & C

• Advancements in Pediatric ITP: What You Need to Know (The France Foundation)
  Room 206

• Measuring the Future: Rethinking Laboratory Testing for NonFactor Approaches in Hemophilia (Pfizer)
  Room 209 A, B & C

​

Sunday, June 22, 13:45 - 14:30  |  Presentation Theaters

• ☆ Time to act: A Subcutaneous Prophylactic Option for Both Hemophilia A and B With Inhibitors (Novo Nordisk Healthcare AG)
  Presentation Theater 1

• Prioritizing Joint Health & Physical Activity in Hemophilia A Patients (Roche / Genentech)
  Presentation Theater 2

• Exploring an Advancement in Hemophilia Care With HYMPAVZI™ (Pfizer)
  Presentation Theater 3

• ☆ Achieve Predictability in Hemophilia B Management With Long-lasting Bleed Protection (CSL Behring)
  Presentation Theater 4​

​

Monday, June 23, 7:00 - 7:45  | Supported Symposium

• Understanding Hereditary Factor X Deficiency to Optimize Clinical Management (Kedrion Biopharma Inc.)
  Room 203 A & B

​

Monday, June 23, 12:15 – 13:30  |  Supported Symposia

• Equitable Access to Prophylaxis in Severe VWD vs Severe Hemophilia A? Worth Thinking About (Octapharma)
  Room 201

• ☆ Exploring the Real-world Impact of ALTUVIIIO® [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] Through Life Transitions (Sanofi)
  Room 202 A & B

• ☆ Exploring Multi-Immune Modulation in the Management of ITP: Current Practices and Future Perspectives (Sanofi)
  Room 204 A, B & C

• Hemophilia Care with Marstacimab: Latest Clinical Data and Future Perspectives (Pfizer)
  Room 206

• Updates in FVllla Mimetics: Advancing Hemophilia Treatment Today and Tomorrow (The France Foundation)
  Room 207 A & B

• ☆ Reaching New Heights: Physician and Patient Perspectives on Gene Therapy (CSL Behring)
  Room 209 A, B & C

 

Monday, June 23, 13:45 – 14:30  |  Presentation Theaters

• Moving Towards Sustained Protection with FVIII in the non-Haemophilia Range (Swedish Orphan Biovitrum AB)
  Presentation Theater 

• ☆ Bridging the Gap: Strategies for Transitioning Patients from Heparin to DOACs
  (Werfen)
  Presentation Theater 2

• ☆ A New Dawn in Hemophilia Care: Clinical Experiences of Antithrombin Lowering (Sanofi)
  Presentation Theater 3

• A Legacy in the Making: HCPs and Community Members Discuss Personal and Collective Experiences in Hemophilia A (Roche / Genentech)
  Presentation Theater 4

​

Tuesday, June 24, 7:00 – 7:45  |  Supported Symposia

• Plasminogen Deficiency: A Rare Multi-Systemic Disorder (Kedrion Biopharma Inc.)
  Room 203 A&B

​​

Tuesday, June 24, 12:15 – 13:30  |  Supported Symposia

• ☆ The Evolution of Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) Management: What’s Next? (Sanofi)
  Room 201

• Entering the Era of Precision Gene Editing for Hemophilia B (Regeneron)
  Room 204 A, B & C

• Evolving Evidence for Factor Concentrates in Surgical Bleeding​​ (Octapharma)
  Room 206

• ☆ Striving Towards Optimal Hemophilia Care Through Patient-Centric Approaches (Novo Nordisk Healthcare AG)
  Room 209 A, B & C

​

Tuesday, June 24, 13:45 - 14:30  |  Presentation Theaters

• Understanding the Role of FVIII in Hemophilia A Hemostasis and Beyond (Octapharma)
  Presentation Theater 1

• When Optimized Anticoagulation for Serious PE Isn't Enough… (Thrombolex, Inc.)
  Presentation Theater 2

• Navigating Treatment Choices in Haemophilia B: What do we Need to Consider? (Swedish Orphan Biovitrum AB)
  Presentation Theater 3

• One Laboratory Platform by Sysmex: The Key to Comprehensive Thrombocytopenia Investigations (Sysmex)
  Presentation Theater 4
   

 

☆ = Promotional bundle partners​